Top

Published in:

01-03-2020 | Multiple Sclerosis | Original Paper

Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis

Authors: Wildéa Lice de Carvalho Jennings Pereira, Tamires Flauzino, Daniela Frizon Alfieri, Sayonara Rangel Oliveira, Ana Paula Kallaur, Andrea Name Colado Simão, Marcell Alysson Batisti Lozovoy, Damacio Ramón Kaimen-Maciel, Michael Maes, Edna Maria Vissoci Reiche

Published in: NeuroMolecular Medicine | Issue 1/2020

Abstract

An association between prolactinemia with disability, clinical forms, and sex of patients with multiple sclerosis (MS) remains unclear. The aim of this study was to evaluate the association of prolactin with clinical forms and accumulating disability over time in patients with MS. A longitudinal study was carried out with 101 patients with relapsing–remitting MS (RRMS) and 19 with progressive forms of MS (ProgMS). The disability over time, as well as prolactin and ferritin serum levels were evaluated at baseline (T0), 8-month follow-up (T8), and 16-month follow-up. The disability at T0, T8, and T16 was higher among patients with ProgMS than those with RRMS. Prolactin and ferritin levels did not differ over time between both groups. Initially, prolactin was associated with MS disability. After introducing age and sex, the effects of prolactin on disability were no longer significant. Prolactin was associated with age and sex, whereby age was positively associated with disability. In the same way, after introducing age and sex, the effects of diagnosis on prolactin levels, as well as the association between prolactin and ferritin, were no longer significant (P = 0.563 and P = 0.599, respectively). Moreover, 21.6% of the variance in the disability was predicted by age (P < 0.001), and sex (P = 0.049), while prolactin was not significant. In conclusion, the effects of prolactin on the disability and clinical forms of MS patients may be spurious results because those correlations reflect the positive associations of age with the disability and the negative association of age with prolactin.

Academia Brasileira De Neurologia. (2016). Recomendações no tratamento da Esclerose Múltipla e Neuromielite Óptica (2nd ed.). São Paulo: Omnifarma.

Alberti, K. G., Eckel, R. H., Grundy, S. M., et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation,120(16), 1640–1645.CrossRefPubMed

Azar, S. T., & Yamout, B. (1999). Prolactin secretion is increased in patients with multiple sclerosis. Endocrine Research,25(2), 207–214. https://doi.org/10.1080/07435809909066142.CrossRefPubMed

Borba, V. V., Zandman-Goddard, G., & Shoenfeld, Y. (2018). Prolactin and autoimmunity. Frontiers in Immunology,9, 1–8.CrossRef

Borchers, A. T., Naguwa, S. M., Keen, C. L., & Gershwin, M. E. (2010). The implications of autoimmunity and pregnancy. Journal of Autoimmunity,34(3), 287–299. https://doi.org/10.1016/j.jaut.2009.11.015.CrossRef

Correale, J., Farez, M. F., & Ysrraelit, M. C. (2014). Role of prolactin in B cell regulation in multiple sclerosis. Journal of Neuroimmunology,269(1–2), 76–86. https://doi.org/10.1016/j.jneuroim.2014.02.007.CrossRefPubMed

Cottrell, D. A., Kremenchutzky, M., Rice, G. P., et al. (1999). The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain,122(Pt 4), 625–639.CrossRefPubMed

Da Costa, R., Szyper-Kravitz, M., Szekanecz, Z., et al. (2011). Ferritin and prolactin levels in multiple sclerosis. Israel Medical Association Journal,13(2), 91–95.

De Giglio, L., Marinelli, F., Prosperini, L., et al. (2015). Relationship between prolactin plasma levels and white matter volume in women with multiple sclerosis. Mediators of Inflammation,2015, 732539. https://doi.org/10.1155/2015/732539.CrossRefPubMedPubMedCentral

Devi, Y. S., & Halperin, J. (2014). Reproductive actions of prolactin mediated through short and long receptor isoforms. Molecular and Cellular Endocrinology,382(1), 400–410. https://doi.org/10.1016/j.mce.2013.09.016.CrossRef

Ferreira, K. P. Z., Oliveira, S. R., Kallaur, A. P., et al. (2017). Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis. Journal of the Neurological Sciences,15(373), 236–241. https://doi.org/10.1016/j.jns.2016.12.039.CrossRef

Gregg, C. (2009). Pregnancy, prolactin and white matter regeneration. J Neurological Sciences,285, 22–27.CrossRef

Gregg, C., Shikar, V., Larsen, P., et al. (2007). White matter plasticity and enhanced remyelination in the maternal CNS. Journal of Neuroscience,21, 1812–1823.CrossRef

Heesen, C., Gold, S. M., Bruhn, M., Mönch, A., & Schulz, K. H. (2002). Prolactin stimulation in multiple sclerosis—An indicator of disease subtypes and activity? Endocrine Research,28(1–2), 9–18.CrossRefPubMed

Huitinga, I., Erkut, Z. A., Van Beurden, D., et al. (2004). Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Annals of Neurology,55, 37–45.CrossRefPubMed

James, P. A., Oparil, S., Carter, B. L., et al. (2014). Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA,311(5), 507–520.CrossRefPubMed

Kira, J., Harada, M., Yamaguchi, Y., et al. (1991). Hyperprolactinemia in multiple sclerosis. Journal of the Neurological Sciences,102, 61–66.CrossRefPubMed

Koch, M., Mostert, J., Arutjunyan, A. V., et al. (2007). Plasma lipid peroxidation and progression of disability in multiple sclerosis. European Journal of Neurology,14, 529–533.CrossRefPubMed

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology,33, 1444–1452.CrossRefPubMed

Langer-Gould, A., Huang, S. M., & Gupta, R. (2009). Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Archives of Neurology,66, 958–963.CrossRefPubMed

Lassmann, H., van Horssen, J., & Mahad, D. (2012). Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews Neurology,8, 647–656.CrossRefPubMed

Lennartsson, A. K., & Jonsdottir, I. H. (2011). Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology,36, 1530–1539.CrossRefPubMed

Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology,46, 907–911.CrossRefPubMed

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., et al. (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology,83(3), 278–286.CrossRefPubMedPubMedCentral

Mackern-Oberti, J. P., Jara, E. L., Riedel, C. A., & Kalergis, A. M. (2011). Hormonal modulation of dendritic cells differentiation, maturation and function: Implications for the initiation and progress of systemic autoimmunity. Archivum immunolgiae et therapiae experimentalis,65(2), 123–136. https://doi.org/10.1007/s00005-016-0418-6.CrossRef

Majumdar, A., & Mangal, N. S. (2013). Hyperprolactinemia. Journal of Human Reproductive Sciences,6(3), 168–175. https://doi.org/10.4103/0974-1208.121400.CrossRefPubMedPubMedCentral

Mellai, M., Giordano, M., D’Alfonso, S., et al. (2003). Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Human Immunology,64(2), 274–284. https://doi.org/10.1016/s0198-8859(02)00804-2.CrossRefPubMed

Moshirzadeh, S., Ghareghozli, K., Harandi, A. A., & Pakdaman, H. (2012). Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse. Journal of Clinical Neuroscience,19(4), 622–623. https://doi.org/10.1016/j.jocn.2011.07.032.CrossRefPubMed

Orbach, H., Zandman-Goddard, G., Amital, H., Barak, V., Szekanecz, Z., Szucs, G., et al. (2007). Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Annals of the New York Academy of Sciences,1109, 385–400.CrossRefPubMed

Ortona, E., Pierdominici, M., Maselli, A., Veroni, C., Aloisi, F., & Shoenfeld, Y. (2016). Sex-based differences in autoimmune diseases. Annali dell Istituto Superiore di Sanita,52(2), 205–212. https://doi.org/10.4415/ann_16_02_12.CrossRefPubMed

Peeva, E., & Zouali, M. (2005). Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunology Letters,101(2), 123–143. https://doi.org/10.1016/j.imlet.2005.05.014.CrossRefPubMed

Pereira Suarez, A. L., Lopez-Rincon, G., Martinez Neri, P. A., & Estrada-Chavez, C. (2015). Prolactin in inflammatory response. Advances in Experimental Medicine and Biology,846, 243–264. https://doi.org/10.1007/978-3-319-12114-7_11.CrossRefPubMed

Polman, C. H., Reingold, S. C., Banwell, B., et al. (2011). Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology,69, 292–302. https://doi.org/10.1002/ana.22366.CrossRefPubMedPubMedCentral

Ringle, C. M., Wende, S., Becker, J.-M. SmartPLS 3. Bönningstedt: SmartPLS, 2015. Retrieved from http://www.smartpls.com.

Sinha, Y. (1995). Structural variants of prolactin: Occurrence and physiological significance. Endocrine Reviews,16, 354–369.CrossRefPubMed

Sospedra, M., & Martin, R. (2016). Immunology of multiple sclerosis. Seminars in Neurology,36, 115–127.CrossRefPubMed

Vera-Lastra, O., Jara, L. J., & Espinoza, L. R. (2002). Prolactin and autoimmunity. Autoimmunity Reviews,1(6), 360–364. https://doi.org/10.1016/S1568-9972(02)00081-2.CrossRefPubMed

Vukusic, S., Hutchinson, M., & Hours, M. (2004). Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of postpartum relapse. Brain,127, 1353–1360.CrossRefPubMed

Yamasaki, K., Horiuchi, I., Minohara, M., et al. (2000). Hyperprolactinemia in optico-spinal multiple sclerosis. Internal Medicine,39, 296–299.CrossRefPubMed

Zhornitsky, S., Yong, V. W., Weiss, S., & Metz, L. M. (2012). Prolactin in multiple sclerosis. Multiple Sclerosis Journal,19(1), 15–23. https://doi.org/10.1177/1352458512458555.CrossRefPubMed

Title: Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis
Authors: Wildéa Lice de Carvalho Jennings Pereira
Tamires Flauzino
Daniela Frizon Alfieri
Sayonara Rangel Oliveira
Ana Paula Kallaur
Andrea Name Colado Simão
Marcell Alysson Batisti Lozovoy
Damacio Ramón Kaimen-Maciel
Michael Maes
Edna Maria Vissoci Reiche
Publication date: 01-03-2020
Publisher: Springer US
Keyword: Multiple Sclerosis
Published in: NeuroMolecular Medicine / Issue 1/2020
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-019-08565-3

At a glance: The STEP trials

Springer Medicine

Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Variation in DNA Repair System Gene as an Additional Modifier of Age at Onset in Spinocerebellar Ataxia Type 3/Machado–Joseph Disease

The Putative Association of TOB1-AS1 Long Non-coding RNA with Immune Tolerance: A Study on Multiple Sclerosis Patients

Butanol Extract of Tinospora cordifolia Ameliorates Cognitive Deficits Associated with Glutamate-Induced Excitotoxicity: A Mechanistic Study Using Hippocampal Neurons

RIP at the Synapse and the Role of Intracellular Domains in Neurons

Mucopolysaccharidosis and Autophagy: Controversies on the Contribution of the Process to the Pathogenesis and Possible Therapeutic Applications

Association of HSPA1B Polymorphisms with Paranoid Schizophrenia in a Polish Population